Raymond James Financial’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Raymond James Financial’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.43M	Sell	31,089 -18,103	-37%	-$802K	﹤0.01%	3609
2025 Q4	$2.02M	Sell	49,192 -29,887	-38%	-$1.2M	﹤0.01%	3270
2025 Q3	$3.07M	Sell	79,079 -5,836	-7%	-$190K	﹤0.01%	2834
2025 Q2	$2.35M	Sell	84,915 -18,758	-18%	-$477K	﹤0.01%	2946
2025 Q1	$2.3M	Sell	103,673 -96,280	-48%	-$1.98M	﹤0.01%	2890
2024 Q4	$3.96M	Buy	+199,953	New	+$4.56M	﹤0.01%	2466

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Raymond James Financial's KNSA Position: Q1 2026 in Review

Raymond James Financial reduced its Kiniksa Pharmaceuticals (KNSA) stake by 37% in Q1 2026, selling an estimated $802K and leaving 31,089 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3609.

Raymond James Financial first reported a position in KNSA in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.96M in Q4 2024. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Raymond James Financial held 31,089 shares of Kiniksa Pharmaceuticals worth $1.43M as of Q1 2026.
Raymond James Financial sold 18,103 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $802K.
Kiniksa Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3609 holding.
Raymond James Financial first reported a position in Kiniksa Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Kiniksa Pharmaceuticals position peaked at $3.96M in Q4 2024.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.